Joinn Laboratories(China)Co.,Ltd. (SHA:603127)
China · Delayed Price · Currency is CNY 37.66
+0.73 (1.98%)
Apr 20, 2026, 3:00 PM CST
SHA:603127 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,658 | 2,018 | 2,376 | 2,268 | 1,517 |
| 1,658 | 2,018 | 2,376 | 2,268 | 1,517 | |
Revenue Growth (YoY) | -17.87% | -15.07% | 4.78% | 49.54% | 40.97% |
Cost of Revenue | 1,376 | 1,498 | 1,395 | 1,187 | 778.89 |
Gross Profit | 281.48 | 520.82 | 981.55 | 1,081 | 737.79 |
Selling, General & Admin | 319.17 | 317.06 | 304.87 | 317.88 | 272.13 |
Research & Development | 87.43 | 92.92 | 96.85 | 77.99 | 47.76 |
Other Operating Expenses | 8.7 | 8.22 | -3.32 | -22.84 | 1.26 |
Operating Expenses | 410.41 | 437.12 | 408.4 | 373.02 | 321.97 |
Operating Income | -128.93 | 83.69 | 573.16 | 708.41 | 415.82 |
Interest Expense | -1.42 | -2.45 | -3.14 | -3.58 | -3.96 |
Interest & Investment Income | 96.2 | 139.24 | 152.13 | 131.23 | 100.72 |
Earnings From Equity Investments | - | - | - | -2.69 | - |
Currency Exchange Gain (Loss) | -9.68 | -0.68 | 12.11 | 27.4 | -60.33 |
Other Non Operating Income (Expenses) | -11.55 | -14.13 | -0.71 | - | -0.76 |
EBT Excluding Unusual Items | -55.38 | 205.68 | 733.54 | 860.77 | 451.5 |
Impairment of Goodwill | -81.54 | - | - | - | - |
Gain (Loss) on Sale of Investments | 447.56 | -127.05 | -245.64 | 32.21 | 157.78 |
Gain (Loss) on Sale of Assets | -0.05 | -0.21 | -0.25 | -0.41 | -0.41 |
Asset Writedown | -2.92 | - | - | 333.07 | - |
Other Unusual Items | 29.83 | 25.62 | 19.3 | 14.37 | 33.14 |
Pretax Income | 337.49 | 104.04 | 506.95 | 1,240 | 642 |
Income Tax Expense | 39.65 | 34.28 | 115.4 | 166.8 | 85.59 |
Earnings From Continuing Operations | 297.84 | 69.76 | 391.55 | 1,073 | 556.42 |
Minority Interest in Earnings | -0 | 4.32 | 5.44 | 1.06 | 1.04 |
Net Income | 297.84 | 74.08 | 396.99 | 1,074 | 557.46 |
Net Income to Common | 297.84 | 74.08 | 396.99 | 1,074 | 557.46 |
Net Income Growth | 302.08% | -81.34% | -63.04% | 92.71% | 76.96% |
Shares Outstanding (Basic) | 745 | 741 | 749 | 747 | 723 |
Shares Outstanding (Diluted) | 745 | 741 | 749 | 751 | 729 |
Shares Change (YoY) | 0.52% | -1.11% | -0.33% | 3.03% | 16.95% |
EPS (Basic) | 0.40 | 0.10 | 0.53 | 1.44 | 0.77 |
EPS (Diluted) | 0.40 | 0.10 | 0.53 | 1.43 | 0.76 |
EPS Growth | 300.00% | -81.13% | -62.94% | 87.10% | 51.32% |
Free Cash Flow | 300.96 | 69.54 | 430.15 | 676.68 | 448.41 |
Free Cash Flow Per Share | 0.40 | 0.09 | 0.57 | 0.90 | 0.61 |
Dividend Per Share | 0.120 | 0.030 | 0.160 | 0.286 | 0.184 |
Dividend Growth | 300.00% | -81.25% | -44.00% | 55.61% | 43.89% |
Gross Margin | 16.98% | 25.80% | 41.30% | 47.68% | 48.64% |
Operating Margin | -7.78% | 4.15% | 24.12% | 31.24% | 27.42% |
Profit Margin | 17.97% | 3.67% | 16.71% | 47.37% | 36.75% |
Free Cash Flow Margin | 18.16% | 3.45% | 18.10% | 29.84% | 29.57% |
EBITDA | -24.51 | 185.32 | 676.51 | 802.6 | 490.27 |
EBITDA Margin | -1.48% | 9.18% | 28.47% | 35.39% | 32.32% |
D&A For EBITDA | 104.42 | 101.63 | 103.36 | 94.19 | 74.45 |
EBIT | -128.93 | 83.69 | 573.16 | 708.41 | 415.82 |
EBIT Margin | -7.78% | 4.15% | 24.12% | 31.24% | 27.42% |
Effective Tax Rate | 11.75% | 32.95% | 22.76% | 13.45% | 13.33% |
Revenue as Reported | 1,658 | 2,018 | 2,376 | - | 1,517 |
Advertising Expenses | 8.59 | 5 | 4.51 | - | 1.42 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.